SK biopharmaceuticals

SK바이오팜 · 326030

Health Care Biotechnology · KOSPI

Large-cap

Market cap US$5B (₩6.9T)

Overview

Company summary coming soon.

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$512.1M

▲ +29.1% YoY

Operating profit · FY2025

US$147.8M

▲ +111.7% YoY

Net income · FY2025

US$183.5M

▲ +11.6% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$257.2M(₩354.9B)	US$396.8M(₩547.6B)	US$512.1M(₩706.7B)
Operating profit	−US$27.2M(−₩37.5B)	US$69.8M(₩96.3B)	US$147.8M(₩203.9B)
Net income	−US$25.6M(−₩35.4B)	US$164.5M(₩227B)	US$183.5M(₩253.3B)

Revenue

Operating profit

Net income

ROE

30.6%

Debt/Eq

45.0%

Op. margin

28.9%

Net margin

35.8%

Rev. YoY

▲ +29.1%

Interactive price history isn't here yet. Would you use it?